Effects of Twice-Daily Injections of Premixed Insulin Analog on Glycemic Control in Type 2 Diabetic Patients.
10.3349/ymj.2010.51.6.845
- Author:
Hiroaki SHIMIZU
1
;
Tsuyoshi MONDEN
;
Mihoko MATSUMURA
;
Nozomi DOMEKI
;
Kikuo KASAI
Author Information
1. Department of Endocrinology and Metabolism, Dokkyo Medical University School of Medicine, Tochigi, Japan. mondent@dokkyomed.ac.jp
- Publication Type:Original Article
- Keywords:
Type 2 diabetes;
postprandial hyperglycemia;
lispro Mix50;
lispro Mix25
- MeSH:
Aged;
Blood Glucose/*analysis;
Body Mass Index;
Body Weight;
Diabetes Mellitus, Type 2/*drug therapy;
Female;
Hemoglobin A, Glycosylated/metabolism;
Humans;
Insulin/administration & dosage/*analogs & derivatives;
Male;
Middle Aged;
Postprandial Period;
Protamines/administration & dosage;
Treatment Outcome
- From:Yonsei Medical Journal
2010;51(6):845-849
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Premixed insulin is effective to improve glycemic control; however, clinicians may be less likely to know which premixed insulin is appropriate for which patients. This study aimed to evaluate the effects of twice-daily injections of premixed insulin lispro on glycemic control in type 2 diabetic patients. MATERIALS AND METHODS: Forty type 2 diabetic patients, who had been treated with twice-daily injections of human protamine mixture 30/70 insulin for at least 12 months, were divided into two groups; one group whose blood glucose 2 hours after breakfast was greater than 200 mg/dL, was switched to lispro mix50, and the other group whose blood glucose 2 hours after breakfast < 200 was switched to lispro mix25. RESULTS: Glycated haemoglobin (HbA1c) significantly improved in the Mix50 group from 8.3% to 7.5% (at 12 weeks; p < 0.05), and to 7.5% (at 24 weeks; p < 0.05). On the other hand, HbA1c levels in the Mix25 group were slightly decreased from 8.1% to 7.7% at 12 weeks (p < 0.05), and to 7.9% at 24 weeks (not significant). Both postprandial plasma glucose and fasting plasma glucose levels were significantly improved in the Mix50 group, but not in the Mix25 group. Overall, 95% of subjects preferred premixed lispro insulin from human insulin in the viewpoint of the timing of insulin injection by questionnaire analysis. CONCLUSION: Switching from human protamine mixture 30/70 insulin to lispro mix50 twice-daily injection therapy in patients with high postprandial plasma glucose could improve their glycemic control and quality of life.
